Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance. Issue 142 (June 2016)
- Record Type:
- Journal Article
- Title:
- Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance. Issue 142 (June 2016)
- Main Title:
- Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance
- Authors:
- Gillet, Benjamin
Ianotto, Jean-Christophe
Mingant, Fanny
Didier, Romain
Gilard, Martine
Ugo, Valérie
Lippert, Eric
Galinat, Hubert - Abstract:
- Abstract: Introduction: In myeloproliferative neoplasms (MPN), aspirin reduces the thrombotic risk. Nevertheless, aspirin resistance may be due to excessive platelet production ("turnover" resistance). Aspirin resistance can also result from a lack of effect of aspirin; this second component is called "intrinsic resistance". Two biological tests are considered reference methods for the assessment of aspirin resistance: TXB2 assay and Light Transmittance Aggregometry (LTA) with arachidonic acid. Materials & methods: We have compared a third method, the Multiple Electrode Aggregometry (MEA), performed with arachidonic acid on the Multiplate® analyzer, with both reference methods. Thirty-six patients with MPN were assessed for aspirin resistance with all three techniques. 30 patients devoid of MPN were used as controls. Results: The three methods were statistically equivalent: LTA and TXB2 were comparable methods (ROC curve AUC = 0.844 > 0.7; LTA cutoff = 67%). At this threshold, LTA had a sensitivity of 73% and a specificity of 96%. MEA (without added aspirin) and TXB2 were also comparable (ROC curve AUC = 0.782; MEA cutoff = 31 U), but at this threshold, 11 patients (30%) were falsely positive with MEA. Last, MEA and LTA were comparable (ROC curve AUC = 0.888; MEA cutoff = 56 U), with a sensitivity of 90% and a specificity of 84.6%. Besides, MEA gave an insight into the mechanism of aspirin resistance (turnover and/or intrinsic). Conclusion: MEA is both rapid and reliable asAbstract: Introduction: In myeloproliferative neoplasms (MPN), aspirin reduces the thrombotic risk. Nevertheless, aspirin resistance may be due to excessive platelet production ("turnover" resistance). Aspirin resistance can also result from a lack of effect of aspirin; this second component is called "intrinsic resistance". Two biological tests are considered reference methods for the assessment of aspirin resistance: TXB2 assay and Light Transmittance Aggregometry (LTA) with arachidonic acid. Materials & methods: We have compared a third method, the Multiple Electrode Aggregometry (MEA), performed with arachidonic acid on the Multiplate® analyzer, with both reference methods. Thirty-six patients with MPN were assessed for aspirin resistance with all three techniques. 30 patients devoid of MPN were used as controls. Results: The three methods were statistically equivalent: LTA and TXB2 were comparable methods (ROC curve AUC = 0.844 > 0.7; LTA cutoff = 67%). At this threshold, LTA had a sensitivity of 73% and a specificity of 96%. MEA (without added aspirin) and TXB2 were also comparable (ROC curve AUC = 0.782; MEA cutoff = 31 U), but at this threshold, 11 patients (30%) were falsely positive with MEA. Last, MEA and LTA were comparable (ROC curve AUC = 0.888; MEA cutoff = 56 U), with a sensitivity of 90% and a specificity of 84.6%. Besides, MEA gave an insight into the mechanism of aspirin resistance (turnover and/or intrinsic). Conclusion: MEA is both rapid and reliable as compared to reference methods. Clinical correlation with risk of re-thrombosis should definitively validate this method and the best cutoff value. Highlights: MEA is comparable to reference methods for aspirin resistance assessment. MEA distinguishes turnover versus intrinsic resistance. Turnover resistance is predominant in patients with myeloproliferative neoplasms. … (more)
- Is Part Of:
- Thrombosis research. Issue 142(2016)
- Journal:
- Thrombosis research
- Issue:
- Issue 142(2016)
- Issue Display:
- Volume 142, Issue 142 (2016)
- Year:
- 2016
- Volume:
- 142
- Issue:
- 142
- Issue Sort Value:
- 2016-0142-0142-0000
- Page Start:
- 26
- Page End:
- 32
- Publication Date:
- 2016-06
- Subjects:
- Aspirin resistance -- Myeloproliferative neoplasms -- Multiple Electrode Aggregometry -- Thromboxane B2 -- Turnover resistance
Thrombosis -- Periodicals
616.135 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00493848 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.thromres.2016.04.006 ↗
- Languages:
- English
- ISSNs:
- 0049-3848
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8820.365000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 628.xml